Subject(s)
Antidepressive Agents/therapeutic use , Lithium Compounds/therapeutic use , Polymorphism, Genetic , Serotonin Plasma Membrane Transport Proteins/genetics , Sleep Deprivation/drug therapy , Adult , Diagnostic and Statistical Manual of Mental Disorders , Female , Humans , Male , Middle Aged , Pindolol/therapeutic use , Psychiatric Status Rating Scales/statistics & numerical data , Psychotic Disorders/complications , Psychotic Disorders/drug therapy , Serotonin 5-HT1 Receptor Antagonists , Serotonin Antagonists/therapeutic use , Sleep Deprivation/complications , Treatment OutcomeABSTRACT
Fluvoxamine 200 mg was administered for 3 months to a group of 43 interferon beta-1b treated patients affected by major depression associated with multiple sclerosis. Despite a 16.3% attrition rate, 79% of patients achieved response. The drug was well tolerated.
Subject(s)
Depressive Disorder, Major/drug therapy , Depressive Disorder, Major/etiology , Fluvoxamine/therapeutic use , Multiple Sclerosis/complications , Selective Serotonin Reuptake Inhibitors/therapeutic use , Adjuvants, Immunologic/therapeutic use , Adult , Drug Administration Schedule , Female , Follow-Up Studies , Humans , Interferon beta-1b , Interferon-beta/therapeutic use , Male , Mental Status Schedule , Middle Aged , Severity of Illness Index , Treatment OutcomeABSTRACT
Recent studies showed that a polymorphism (T to C nucleotide substitution) in the 3' flanking region of the human CLOCK gene is associated with diurnal preferences of human healthy subjects, with higher "eveningness" in subjects carrying at least one copy of the C allele. We investigated the possible role of CLOCK gene polymorphism in the regulation of diurnal mood fluctuations during a major depressive episode. Sample (n = 101) was collected, in the context of previously reported trials, among patients affected by bipolar disorder type I, depressive episode without psychotic features, free of psychotropic medications. Perceived mood levels were assessed three times a day with self-administered visual analogue scales. Genotype groups showed no significant difference in diurnal mood fluctuations. When stratifying the sample by including only patients with an adequate period of observation (duration of illness higher than 5 years, n = 69), we post-hoc observed a significantly higher recurrence rate in homozygotes for the C variant, which was almost double than that of the other genotype groups. This preliminary observation leads to hypothesize a role for the CLOCK gene polymorphism in the regulation of long-term illness recurrence in bipolar disorder. Given the post-hoc nature of the finding, replication in independent samples is necessary to confirm it.
